Cantor Fitzgerald Has Weak Outlook for CNTX FY2025 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Context Therapeutics in a research note issued on Thursday, November 6th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($0.35) for the year, down from their previous forecast of ($0.31). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Cantor Fitzgerald also issued estimates for Context Therapeutics’ FY2026 earnings at ($0.28) EPS.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01).

Other equities analysts have also recently issued research reports about the stock. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, November 6th. HC Wainwright upped their price target on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. Finally, Guggenheim began coverage on Context Therapeutics in a research note on Thursday, September 18th. They issued a “buy” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.40.

Context Therapeutics Trading Up 7.1%

NASDAQ:CNTX opened at $1.20 on Monday. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.10. The stock has a market capitalization of $110.26 million, a price-to-earnings ratio of -5.00 and a beta of 1.94. The firm has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $0.85.

Hedge Funds Weigh In On Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Clear Harbor Asset Management LLC raised its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 92,804 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned approximately 0.10% of Context Therapeutics worth $90,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.